WEKO3
アイテム
{"_buckets": {"deposit": "3c3c1ba6-6d7b-4bbf-921f-ccd7ec9b6e90"}, "_deposit": {"created_by": 1, "id": "557", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "557"}, "status": "published"}, "_oai": {"id": "oai:showa.repo.nii.ac.jp:00000557", "sets": ["65"]}, "author_link": ["2899", "2896", "2894", "2900", "2898", "2895", "2897"], "item_10002_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "30", "bibliographicPageStart": "19", "bibliographicVolumeNumber": "28", "bibliographic_titles": [{"bibliographic_title": "The Showa University journal of medical sciences"}]}]}, "item_10002_description_6": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "To evaluate prognostic factors for recurrence after tegafur-uracil plus leucovorin (UFT/LV) adjuvant chemotherapy in patients with colorectal cancer (CRC). Consecutive patients with CRC who received UFT/LV as adjuvant chemotherapy at Showa University Hospital between June 2005 and December 2008 were included in the study, 5-year disease-free survival (DFS) and overall survival (OS) rates were estimated, and prognostic factors for recurrence were analyzed using the Cox proportional hazards model for multivariate analysis. Of 92 patients included in the study, 17 (18.5%) had disease recurrence. The 5-year DFS and OS rates were 82.2% and 91.9%, respectively. In the multivariate analysis, preoperative CA19-9 level>37U/ml, emergency operation, and T4 lesions were independent significant prognostic factors after treatment with UFT/LV adjuvant chemotherapy. The three independent prognostic factors —T4 lesions, emergency operation, and high preoperative CA19-9 levels— may be useful for decision-making regarding whether patients should receive 5-fluouracil-based or L-oxaliplatin-based adjuvant chemotherapy. As this was a single-institution study with a small number of patients, our findings need to be confirmed in larger multicenter studies.", "subitem_description_type": "Abstract"}]}, "item_10002_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Showa University Society"}]}, "item_10002_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.15369/sujms.28.19", "subitem_relation_type_select": "DOI"}}]}, "item_10002_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10781651", "subitem_source_identifier_type": "NCID"}]}, "item_10002_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0915-6380 ", "subitem_source_identifier_type": "ISSN"}]}, "item_10002_text_26": {"attribute_name": "アイテムタイプ", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌 / Departmental Bulletin Paper"}]}, "item_10002_text_27": {"attribute_name": "POS_INDEX", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌/The Showa University journal of medical sciences/Vol.28(2016)/No.1"}]}, "item_10002_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "WATANABE, Makoto"}], "nameIdentifiers": [{"nameIdentifier": "2894", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MURAKAMI, Masahiko"}], "nameIdentifiers": [{"nameIdentifier": "2895", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OZAWA, Yoshiaki"}], "nameIdentifiers": [{"nameIdentifier": "2896", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "GOTO, Satoru"}], "nameIdentifiers": [{"nameIdentifier": "2897", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUJIMORI, Akira"}], "nameIdentifiers": [{"nameIdentifier": "2898", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OTSUKA, Koji"}], "nameIdentifiers": [{"nameIdentifier": "2899", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "AOKI, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "2900", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "S28_19.pdf", "filesize": [{"value": "459.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 459200.0, "url": {"label": "S28_19.pdf", "url": "https://showa.repo.nii.ac.jp/record/557/files/S28_19.pdf"}, "version_id": "abaac285-89f4-48b8-9d0b-d6d021a45e6b"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer ", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer ", "subitem_title_language": "en"}]}, "item_type_id": "10002", "owner": "1", "path": ["65"], "permalink_uri": "https://showa.repo.nii.ac.jp/records/557", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-02-14"}, "publish_date": "2017-02-14", "publish_status": "0", "recid": "557", "relation": {}, "relation_version_is_last": true, "title": ["Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer "], "weko_shared_id": 1}
Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer
https://showa.repo.nii.ac.jp/records/557
https://showa.repo.nii.ac.jp/records/55763354956-045e-496a-8eac-a20786f7471b
名前 / ファイル | ライセンス | アクション |
---|---|---|
S28_19.pdf (459.2 kB)
|
|
Item type | 学内発行雑誌 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-02-14 | |||||
タイトル | ||||||
タイトル | Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ | departmental bulletin paper | |||||
著者 |
WATANABE, Makoto
× WATANABE, Makoto× MURAKAMI, Masahiko× OZAWA, Yoshiaki× GOTO, Satoru× FUJIMORI, Akira× OTSUKA, Koji× AOKI, Takeshi |
|||||
書誌情報 |
The Showa University journal of medical sciences 巻 28, 号 1, p. 19-30, 発行日 2016-03 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | To evaluate prognostic factors for recurrence after tegafur-uracil plus leucovorin (UFT/LV) adjuvant chemotherapy in patients with colorectal cancer (CRC). Consecutive patients with CRC who received UFT/LV as adjuvant chemotherapy at Showa University Hospital between June 2005 and December 2008 were included in the study, 5-year disease-free survival (DFS) and overall survival (OS) rates were estimated, and prognostic factors for recurrence were analyzed using the Cox proportional hazards model for multivariate analysis. Of 92 patients included in the study, 17 (18.5%) had disease recurrence. The 5-year DFS and OS rates were 82.2% and 91.9%, respectively. In the multivariate analysis, preoperative CA19-9 level>37U/ml, emergency operation, and T4 lesions were independent significant prognostic factors after treatment with UFT/LV adjuvant chemotherapy. The three independent prognostic factors —T4 lesions, emergency operation, and high preoperative CA19-9 levels— may be useful for decision-making regarding whether patients should receive 5-fluouracil-based or L-oxaliplatin-based adjuvant chemotherapy. As this was a single-institution study with a small number of patients, our findings need to be confirmed in larger multicenter studies. | |||||
DOI | ||||||
関連識別子 | 10.15369/sujms.28.19 | |||||
出版者 | ||||||
出版者 | Showa University Society | |||||
ISSN | ||||||
収録物識別子 | 0915-6380 | |||||
著者版フラグ | ||||||
出版タイプ | VoR |